Amarin Reports Q4 Revenue of $49.2M, Down from $62.3M Last Year
Reports Q4 revenue $49.2M vs. $62.3M last year. "Our performance in the fourth quarter and full year of 2025 confirmed both the initial impact and long-term potential of our strategic initiatives and re-imagined operating model," said Aaron Berg, President and Chief Executive Officer of Amarin. "We have entered 2026 from an improved position of market, operational, and financial strength. We have maintained our U.S. leading market share for VASCEPA and are actively expanding our presence in Europe for VAZKEPA via our long-term partnership agreement with Recordati S.p.A., strengthening our now fully partnered international commercial strategy. We are a leaner organization, having made great progress in reducing costs and narrowing our losses, while continuing to invest in expanding an already formidable body of scientific knowledge that supports our global VASCEPA/VAZKEPA franchise and its proven ability to reduce cardiovascular risk. While work remains, we are encouraged by our progress and continue to examine strategic actions to maximize future shareholder value and options regarding management of capital."
Trade with 70% Backtested Accuracy
Analyst Views on AMRN
About AMRN
About the author
Amarin Misses Q4 2025 Revenue Forecasts, Shares Drop
- Revenue Decline: Amarin reported total revenue of $49.2 million for Q4 2025, reflecting a ~21% year-over-year drop, indicating a contraction after two consecutive quarters of growth, which highlights a weakening market demand.
- Product Sales Drop: The company's product revenue fell ~23% year-over-year to $46.5 million, primarily due to a 74% decline in overseas sales, significantly impacting overall performance, especially with reduced stocking orders ahead of the market launch.
- Improved Net Loss: Despite the revenue decline, Amarin's net loss improved from $48.6 million in the prior year to $1.2 million, largely due to a ~31% reduction in operating expenses, demonstrating effective cost control from restructuring efforts.
- Positive Cash Flow: Amarin achieved positive cash flow in Q4, with cash and cash equivalents increasing ~11% year-over-year to $134.7 million and no debt as of December 31, positioning the company well for future growth.
Amarin Q4 Earnings: Revenue Decline but Cash Increases
- Earnings Highlights: Amarin reported Q4 GAAP EPS of $0.00, beating expectations by $0.01, indicating stability in profitability despite overall revenue challenges.
- Revenue Decline: Q4 revenue was $49.2M, down 21.0% year-over-year, missing estimates by $1.42M, reflecting potential pressure on future performance due to weak market demand.
- Cash Position: As of December 31, 2025, Amarin's total cash and investments reached $302.6M, an increase of $8.4M from $294.2M in 2024, demonstrating effective cash management.
- Debt-Free Status: Amarin remained debt-free as of December 31, 2025, providing flexibility for future investments and expansions, thereby enhancing its financial health.
Amarin Scheduled to Announce Q4 Earnings on February 25
- Earnings Announcement Schedule: Amarin is set to release its Q4 2024 earnings on February 25 before market open, with a consensus EPS estimate of $0.07, improving from -$0.02 in Q4 2024, indicating a potential recovery in profitability.
- Revenue Expectations Decline: The anticipated revenue for Q4 is $50.62 million, reflecting an 18.7% year-over-year decline, suggesting that the company is facing competitive pressures that could impact investor confidence moving forward.
- Historical Performance: Over the past two years, Amarin has beaten EPS estimates 100% of the time and revenue estimates 63% of the time, demonstrating its reliability in financial forecasting and performance.
- 2025 Outlook: Amarin expects full-year 2025 revenue to align with estimates, indicating confidence in future business development despite current short-term challenges.
Amarin Advances VASCEPA with Over 25 Million Global Prescriptions and New Therapy Insights
- Global Prescription Volume: Amarin's VASCEPA®/VAZKEPA® has surpassed 25 million prescriptions worldwide, demonstrating its broad acceptance and efficacy in cardiovascular treatment, thereby solidifying the company's market leadership.
- Therapeutic Innovation: The emergence of new therapies is expected to expand the use of existing treatment options, including VASCEPA, helping to meet the needs of tens of millions of cardiovascular disease patients globally, thus enhancing patient access and treatment outcomes.
- Clinical Evidence Support: According to the 2018 REDUCE-IT study, VASCEPA demonstrated a 25% reduction in cardiovascular events when used in conjunction with statin therapy, providing robust clinical support for its application in cardiovascular risk management.
- Market Expansion Plans: Amarin has signed a long-term exclusive licensing agreement with Recordati S.p.A. to commercialize VAZKEPA across 59 countries, further enhancing its influence in the European market and expected to drive future sales growth.
Daily Upgrade Report for Validea Kenneth Fisher Strategy - December 9, 2025
Validea's Upgrade for AMRN: Validea's Price/Sales Investor model, based on Kenneth Fisher's strategy, upgraded Amarin Corporation PLC (AMRN) from 28% to 60% due to improved fundamentals and valuation, indicating growing interest in the stock.
Company Overview: Amarin Corporation is a pharmaceutical company focused on developing therapeutics for cardiovascular health, primarily through its lead product, Vascepa, which is used to reduce triglyceride levels in patients with severe hypertriglyceridemia.
Kenneth Fisher's Background: Kenneth Fisher, a prominent money manager and author, is known for popularizing the price/sales ratio as a stock evaluation tool and is the founder of Fisher Investments, located in a forest preserve to encourage independent thinking away from Wall Street.
Validea's Investment Research: Validea provides investment research based on the strategies of successful investors like Warren Buffett and Benjamin Graham, offering stock analysis and model portfolios aimed at long-term market outperformance.
New Analysis from REDUCE-IT® on Aspirin Unveiled at AHA Scientific Sessions 2025 Confirms VASCEPA®/VAZKEPA® (Icosapent Ethyl) Lowers Cardiovascular Events in High-Risk Individuals
New Analysis on Icosapent Ethyl: A post hoc analysis from the REDUCE-IT study shows that icosapent ethyl significantly reduces cardiovascular events in high-risk patients, regardless of aspirin use, reinforcing its role in comprehensive cardiovascular risk management.
FDA Update on Fibrates: The FDA has updated labeling for fibrates, indicating they do not provide cardiovascular benefits when used with statins, highlighting the need for more effective therapies to address residual cardiovascular risk.
Commitment to Cardiovascular Care: Amarin Corporation emphasizes its dedication to advancing cardiovascular care and raising awareness about the importance of FDA-approved therapies like VASCEPA (icosapent ethyl) for patients with elevated triglycerides.
Efficacy and Safety Profile: The analysis indicates that icosapent ethyl offers cardiovascular protection beyond standard therapies without additional safety concerns, addressing a critical evidence gap in cardiovascular treatment.
Amarin Misses Q4 2025 Revenue Forecasts, Shares Drop
- Revenue Decline: Amarin reported total revenue of $49.2 million for Q4 2025, reflecting a ~21% year-over-year drop, indicating a contraction after two consecutive quarters of growth, which highlights a weakening market demand.
- Product Sales Drop: The company's product revenue fell ~23% year-over-year to $46.5 million, primarily due to a 74% decline in overseas sales, significantly impacting overall performance, especially with reduced stocking orders ahead of the market launch.
- Improved Net Loss: Despite the revenue decline, Amarin's net loss improved from $48.6 million in the prior year to $1.2 million, largely due to a ~31% reduction in operating expenses, demonstrating effective cost control from restructuring efforts.
- Positive Cash Flow: Amarin achieved positive cash flow in Q4, with cash and cash equivalents increasing ~11% year-over-year to $134.7 million and no debt as of December 31, positioning the company well for future growth.
Amarin Q4 Earnings: Revenue Decline but Cash Increases
- Earnings Highlights: Amarin reported Q4 GAAP EPS of $0.00, beating expectations by $0.01, indicating stability in profitability despite overall revenue challenges.
- Revenue Decline: Q4 revenue was $49.2M, down 21.0% year-over-year, missing estimates by $1.42M, reflecting potential pressure on future performance due to weak market demand.
- Cash Position: As of December 31, 2025, Amarin's total cash and investments reached $302.6M, an increase of $8.4M from $294.2M in 2024, demonstrating effective cash management.
- Debt-Free Status: Amarin remained debt-free as of December 31, 2025, providing flexibility for future investments and expansions, thereby enhancing its financial health.
Amarin Scheduled to Announce Q4 Earnings on February 25
- Earnings Announcement Schedule: Amarin is set to release its Q4 2024 earnings on February 25 before market open, with a consensus EPS estimate of $0.07, improving from -$0.02 in Q4 2024, indicating a potential recovery in profitability.
- Revenue Expectations Decline: The anticipated revenue for Q4 is $50.62 million, reflecting an 18.7% year-over-year decline, suggesting that the company is facing competitive pressures that could impact investor confidence moving forward.
- Historical Performance: Over the past two years, Amarin has beaten EPS estimates 100% of the time and revenue estimates 63% of the time, demonstrating its reliability in financial forecasting and performance.
- 2025 Outlook: Amarin expects full-year 2025 revenue to align with estimates, indicating confidence in future business development despite current short-term challenges.
Amarin Advances VASCEPA with Over 25 Million Global Prescriptions and New Therapy Insights
- Global Prescription Volume: Amarin's VASCEPA®/VAZKEPA® has surpassed 25 million prescriptions worldwide, demonstrating its broad acceptance and efficacy in cardiovascular treatment, thereby solidifying the company's market leadership.
- Therapeutic Innovation: The emergence of new therapies is expected to expand the use of existing treatment options, including VASCEPA, helping to meet the needs of tens of millions of cardiovascular disease patients globally, thus enhancing patient access and treatment outcomes.
- Clinical Evidence Support: According to the 2018 REDUCE-IT study, VASCEPA demonstrated a 25% reduction in cardiovascular events when used in conjunction with statin therapy, providing robust clinical support for its application in cardiovascular risk management.
- Market Expansion Plans: Amarin has signed a long-term exclusive licensing agreement with Recordati S.p.A. to commercialize VAZKEPA across 59 countries, further enhancing its influence in the European market and expected to drive future sales growth.
Daily Upgrade Report for Validea Kenneth Fisher Strategy - December 9, 2025
Validea's Upgrade for AMRN: Validea's Price/Sales Investor model, based on Kenneth Fisher's strategy, upgraded Amarin Corporation PLC (AMRN) from 28% to 60% due to improved fundamentals and valuation, indicating growing interest in the stock.
Company Overview: Amarin Corporation is a pharmaceutical company focused on developing therapeutics for cardiovascular health, primarily through its lead product, Vascepa, which is used to reduce triglyceride levels in patients with severe hypertriglyceridemia.
Kenneth Fisher's Background: Kenneth Fisher, a prominent money manager and author, is known for popularizing the price/sales ratio as a stock evaluation tool and is the founder of Fisher Investments, located in a forest preserve to encourage independent thinking away from Wall Street.
Validea's Investment Research: Validea provides investment research based on the strategies of successful investors like Warren Buffett and Benjamin Graham, offering stock analysis and model portfolios aimed at long-term market outperformance.
New Analysis from REDUCE-IT® on Aspirin Unveiled at AHA Scientific Sessions 2025 Confirms VASCEPA®/VAZKEPA® (Icosapent Ethyl) Lowers Cardiovascular Events in High-Risk Individuals
New Analysis on Icosapent Ethyl: A post hoc analysis from the REDUCE-IT study shows that icosapent ethyl significantly reduces cardiovascular events in high-risk patients, regardless of aspirin use, reinforcing its role in comprehensive cardiovascular risk management.
FDA Update on Fibrates: The FDA has updated labeling for fibrates, indicating they do not provide cardiovascular benefits when used with statins, highlighting the need for more effective therapies to address residual cardiovascular risk.
Commitment to Cardiovascular Care: Amarin Corporation emphasizes its dedication to advancing cardiovascular care and raising awareness about the importance of FDA-approved therapies like VASCEPA (icosapent ethyl) for patients with elevated triglycerides.
Efficacy and Safety Profile: The analysis indicates that icosapent ethyl offers cardiovascular protection beyond standard therapies without additional safety concerns, addressing a critical evidence gap in cardiovascular treatment.
